ME/CFS Science @mecfsscience.org · 14/07/20266) The main result is shown in the figure below. Temelimab had no effect on fatigue, and the same null results were seen for the secondary outcomes, including several cognitive tests and biomarkers. 160
ME/CFS Science @mecfsscience.org · 14/07/20267) The trial was sponsored by the Swiss biopharma company GeNeuro, which makes the drug. A couple of years ago, a randomized trial of Temelimab in multiple sclerosis also failed on its primary outcome. pubmed.ncbi.nlm.nih.... 150
ME/CFS Science @mecfsscience.org · 14/07/20268 ) In the Long Covid trial, the authors conclude: "The absence of a treatment effect across fatigue, cognitive, and functional outcomes in our study may suggest that HERV-W ENV-associated pathways are not dominant drivers of symptoms [...]" 181
